|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Hiroshi_Nomura
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:focusArea
|
infectious diseases
neurology
oncology
psychiatry
regenerative medicine
|
|
gptkbp:formerName
|
gptkb:Dainippon_Sumitomo_Pharma
|
|
gptkbp:founded
|
1897
|
|
gptkbp:headquarters_location
|
gptkb:Osaka,_Japan
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
JP3495000006
|
|
gptkbp:member
|
gptkb:Sumitomo_Group
|
|
gptkbp:notableProduct
|
gptkb:Aptiom
gptkb:Latuda
gptkb:Lunesta
gptkb:Cymbalta
|
|
gptkbp:numberOfEmployees
|
about 7,000
|
|
gptkbp:officialWebsite
|
https://www.sumitomo-pharma.com/
|
|
gptkbp:parentOrganization
|
gptkb:Sumitomo_Group
|
|
gptkbp:products
|
pharmaceutical drugs
|
|
gptkbp:revenue
|
over 500 billion yen (recent years)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4506
|
|
gptkbp:subsidiary
|
gptkb:Sumitomo_Pharma_America
gptkb:Sumitovant_Biopharma
|
|
gptkbp:bfsParent
|
gptkb:Sumitomo_Group
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sumitomo Pharma
|